Revisiting the High-Benefit Patient: Generic Machine Learning Inference for Intensive Blood Pressure Control
Habibdoust, A.; Song, X.
Show abstract
We applied the model-free GenericML framework using robust estimators (the Best Linear Predictor, Group Average Treatment Effects, and baseline profile classification) to reassess treatment effect heterogeneity (HTE) of intensive blood pressure (BP) using pooled data from two large-scale randomized control trials on BP controls. Among 10,712 participants with up to three years of follow-up, we estimated the differential risks of the primary cardiovascular outcome. Intensive BP control produced a modest average risk reduction (BLP b2 =-0.0136), but evidence for HTE was not statistically significant (BLP b2; p = 0.443; GATES top bottom contrast p = 0.471). Although CLAN grouped participants with metabolically adverse profiles into the highest predicted-benefit stratum, their treatment response did not differ significantly from that of the lowest-benefit group. Overall, while machine learning can identify clusters of high-risk baseline phenotypes, group-level inference revealed no meaningful HTE, underscoring the need for caution when interpreting individualized treatment predictions.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis 95%
- Genetic variants related to antihypertensive targets inform drug efficacy and side effects 93%
- Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study 92%
Similar papers in this journal
- Weight change and the incidence of cardiovascular diseases in adults with normal weight, overweight and obesity without chronic diseases; emulating trials using electronic health records 94%
- Negative Control Exposures: Causal effect Identifiability and Use in Probabilistic-Bias and Bayesian Analyses with Unmeasured Confounders 90%
- Incorporating data from multiple endpoints in the analysis of clinical trials: example from RSV vaccines 90%
Similar papers in this journal
- Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study 96%
- Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials 91%
- Joint Association of Polygenic Risk and Social Determinants of Health with Coronary Heart Disease in the United States 91%
Similar papers in this journal
- Biomarker panels for improved risk prediction and enhanced biological insights in patients with atrial fibrillation 93%
- A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood 92%
- Evaluating the cost-effectiveness of polygenic risk score-stratified screening for abdominal aortic aneurysm 92%
Similar papers in this journal
- Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: an individual-based modelling study 93%
- Robust causal inference for long-term policy decisions: cost effectiveness of interventions for obesity using Mendelian randomization 92%
- Differential impact of Covid-19 on incidence of diabetes mellitus and cardiovascular diseases in acute, post-acute and long Covid-19: population-based cohort study in the United Kingdom 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.